Salvage chemotherapy with paclitaxel in platinum-resistant advanced ovarian cancer patients

M. Bruzzone, E. Calsafados, L. Miglietta, D. Amoroso, F. Pedulla, P. G. Giannessi, M. C. Locatelli, A. D'Antona, G. Foglia, S. Mammoliti, F. Turno, A. Gentile, F. Nicosia, G. Luporini, N. Ragni, F. Boccardo

Research output: Contribution to journalArticlepeer-review


Encouraging results with Paclitaxel are reported in ovarian cancer patients relapsing and progressing after platinum-based chemotherapy; however, the two populations have different probabilities of a response to a second-line treatment. Here we report the results achieved in 39 patients with platinum-refractory ovarian cancer, treated with Paclitaxel 175 mg/qm 2 (or 135 mg/m 2 if heavily pretreated) using 3-hour intravenous infusion every 3 weeks, in an attempt to verify the activity of this drug in platinum-resistant patients. The toxicity was mild to moderate and primarily hematologic and neurologic. The objective response rate is 12.8% with no complete responses. The response duration was brief and the median survival 6 (range 1-17) months. An accurate cost-benefit balance is necessary before routinely use of Paclitaxel in platinum-refractory patients. Further research is needed to determine the optimal role of Paclitaxel in the whole therapeutic strategy for ovarian cancer.

Original languageEnglish
Pages (from-to)349-353
Number of pages5
Issue number5
Publication statusPublished - Sep 1996


  • Ovarian cancer
  • Paclitaxel
  • Salvage therapy, ovarian cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Salvage chemotherapy with paclitaxel in platinum-resistant advanced ovarian cancer patients'. Together they form a unique fingerprint.

Cite this